Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1811983 | 0.93 | ADORA1 (0.44) | KDM4EADORA1HDAC9RORC | |
| SCHEMBL1810125 | 0.92 | KDM4E (0.42) | KDM4EADORA1P2RX7RORC | |
| SCHEMBL1818962 | 0.87 | ADORA1 (0.42) | KDM4EADORA1CYP3A4CYP2C9ALDH1A1 | |
| SCHEMBL1815547 | 0.85 | KDM4E (0.42) | KDM4EADORA1HDAC9RORCCYP3A4 | |
| SCHEMBL1817001 | 0.84 | ADORA1 (0.48) | ADORA1CYP3A4CYP2C9ALDH1A1 | |
| SCHEMBL1809503 | 0.82 | ADORA1 (0.43) | KDM4EADORA1ALDH1A1 | |
| SCHEMBL1817101 | 0.81 | SMN1; SMN2 (0.47) | KDM4EP2RX7CYP3A4CYP2C9ALDH1A1 | |
| SCHEMBL1816111 | 0.81 | KMT2A (0.47) | KDM4EL3MBTL1CYP3A4CYP2C9ALDH1A1 | |
| SCHEMBL1814347 | 0.80 | TAS2R14 (0.45) | ADORA1 | |
| SCHEMBL1819947 | 0.79 | ADORA1 (0.69) | ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2321296-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-05-18 | — | — | EP | disclosed |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-22 | — | — | US | disclosed |
| WO-2010020363-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | CYP3A5, ABAT, TPMT | KDM4E 2516/4885ADORA1 724/4885P2RX7 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.